Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 72 of the 75 references it cites were found in a registry or an index.

Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome

Grundy, Scott M · 1998 · The American Journal of Cardiology

Abstract

The importance of high serum cholesterol, especially a high level of low-density lipoprotein (LDL) cholesterol, as a risk factor for coronary artery disease is well established. Likewise, efficacy for decreasing risk for coronary artery disease by LDL-lowering therapy has recently been documented through clinical trials. However, many high-risk patients manifest elevated serum triglyceride levels, and the role of hypertriglyceridemia in causation of coronary artery disease remains to be elucidated. Nonetheless, there is growing evidence that hypertriglyceridemia is a marker for increased risk for coronary artery disease; in fact, it can serve as a marker for several atherogenic factors. These factors include increased concentrations of atherogenic triglyceride-rich lipoproteins; the atherogenic lipoprotein phenotype, or lipid triad; and the metabolic syndrome. The lipid triad consists of elevated serum triglycerides, small LDL particles, and low high-density lipoprotein (HDL) cholesterol. The metabolic syndrome includes the coexistence of the lipid triad, elevated blood pressure, insulin resistance (plus glucose intolerance), and a prothrombotic state. Many previous studies indicate that hypertriglyceridemia is strongly associated with all of these atherogenic factors. The clinical approach to treatment of patients with hypertriglyceridemia thus requires a broad-based strategy that includes reduction of atherogenic triglyceride-rich lipoproteins, reversal of the lipid triad,…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0002-9149(98)00033-2

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 75 references

Research works printed but not linked: 2

  1. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease, Lancet, 344, 1383
  2. Grundy, 1992, Two different views of the relationship of hypertriglyceridemia to coronary artery disease, Arch Intern Med, 152, 28, 10.1001/archinte.1992.00400130054004 · doi:10.1001/archinte.1992.00400130054004

Cited by

See all 525

Metadata

Authors
Grundy, S. M.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Grundy, Scott M
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
1998-02
Volume
81
Issue
4
Pages
18B-25B
ISSN
0002-9149 (ISSN-L)
OpenAlex
W2136841005
Cited by
525
References
75
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 17 · 2021: 10 · 2020: 16 · 2019: 15 · 2018: 14 · 2017: 17 · 2016: 15 · 2015: 19 · 2014: 21 · 2013: 18 · 2012: 22
FWCI
4.47
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The American Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
hypertriglyceridemia, atherogenic dyslipidemia, metabolic syndrome, triglyceride-rich lipoproteins, small dense LDL, low HDL cholesterol, coronary artery disease risk, insulin resistance, hypercoagulability, LDL-C lowering therapy, hypertriglyceridemia treatment
MeSH terms
Animals, Hypolipidemic Agents, Arteriosclerosis, Coronary Disease, Humans, Hyperlipidemias, Hypertension, Insulin Resistance, Cholesterol, HDL, Lipoproteins, LDL, Cholesterol, LDL, Lipoproteins, VLDL, Risk Factors, Syndrome, Triglycerides, Hypertriglyceridemia, Multivariate Analysis, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. https://app.cochat.ai/papers/10.1016/s0002-9149(98)00033-2
The paper
Grundy, S. M. (1998). Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. The American Journal of Cardiology. https://doi.org/10.1016/s0002-9149(98)00033-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.